A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Clinical Trial ID NCT02367196

Rank	Title	Journal	Year	PubWeight™‹?›
1	Combination cancer immunotherapies tailored to the tumour microenvironment.	Nat Rev Clin Oncol	2015	1.54
2	Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.	Clin Cancer Res	2015	0.92
3	Macrophage engulfment of a cell or nanoparticle is regulated by unavoidable opsonization, a species-specific 'Marker of Self' CD47, and target physical properties.	Curr Opin Immunol	2015	0.83
4	Original insights on thrombospondin-1-related antireceptor strategies in cancer.	Front Pharmacol	2015	0.82
5	Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.	Cell Death Differ	2016	0.82
6	Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer.	J Cell Commun Signal	2015	0.82
7	A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.	Oncotarget	2016	0.81
8	Role of Erythrocyte CD47 in Intracerebral Hematoma Clearance.	Stroke	2016	0.81
9	Secreted Thrombospondin-1 Regulates Macrophage Interleukin-1β Production and Activation through CD47.	Sci Rep	2016	0.75
10	Myeloid Cell Origins, Differentiation, and Clinical Implications.	Microbiol Spectr	2016	0.75